Natera partners with Angiex to use Signatera ctDNA test in AGX101 Phase I trial monitoring
NTRA•AGX101 trial context
AGX101 targets TM4SF1 to deliver a cytotoxic payload to tumor cells, as well as tumor-associated endothelial cells, aiming to hit tumor vasculature.
The data are intended to support development decisions for AGX101 by clarifying response when radiology results are uncertain.
Signatera collaboration with Angiex
Natera entered a Signatera collaboration with Angiex to track treatment response in Angiex’s Phase I AGX101 solid-tumor trial.
The agreement calls for longitudinal Signatera ctDNA testing during AGX101 dosing to assess molecular response alongside imaging.
